- Terapie mnohočetného spinaliomu pomocí anti-PD-L12020 | Third Faculty of Medicine
- Current treatment options for renal cell carcinoma and outlook2020 | Publication without faculty affiliation
- Merkel cell cancer2019 | Third Faculty of Medicine
- Novel Treatment Options in Metastatic Esophageal Carcinoma: Checkpoint Inhibitors in Combination Therapies2023 | Second Faculty of Medicine, First Faculty of Medicine, Faculty of Physical Education and Sport
- A long-term survivor female patient with metastatic melanoma after treatment with pembrolizumab in the third line2020 | First Faculty of Medicine
- Avelumab in the therapy of urothelial carcinoma2021 | First Faculty of Medicine
- Durvalumab in the treatment of lung cancer2019 | Second Faculty of Medicine
- Atypical response to anti-PD-1 therapy followed by long-term survival in non-small cell lung cancer - case reports2020 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Avelumab plus axitinib combination in treating metastatic renal cell carcinoma2022 | First Faculty of Medicine
- Abrogation of IFN-gamma Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade2020 | Faculty of Science
- Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade2020 | Faculty of Science
- Suppression of IL-10 production by activated B cells via a cell contact-dependent cyclooxygenase-2 pathway upregulated in IFN-γ-treated mesenchymal stem cells2016 | Faculty of Science
- A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens2020 | Publication without faculty affiliation
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study2018 | Second Faculty of Medicine
